Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 68. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Direct-to-consumer services: improving access to care for people with diabetes and obesity1442
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale1034
South Africa to produce insulin for Africa in 2024708
Reassessing driving safety in diabetes664
Better testing and labelling of drugs for people with obesity652
Anand Hardikar: a scientific nomad searching for the truth342
What's preventing us from curbing the obesity crisis?300
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98292
Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study265
Artificial intelligence for interpreting diabetes data using clinician-curated benchmarks265
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?263
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality244
Implications of technology guidelines for low-income and middle-income countries217
Artificial intelligence and diabetes: time for action and caution209
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions207
World Health Assembly ratifies first global diabetes targets197
Clinical features, investigation, and management of Addison's disease196
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity186
A framework for improving diabetes care in humanitarian emergencies181
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice168
Specific cortisol blockade in Cushing's syndrome151
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p150
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial150
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial141
Type 1 diabetes screening: need for ethical, equity, and health systems perspective137
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial134
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2126
Challenging diabetes stigma starts and ends with all of us121
What does renal failure teach us about our National Health System?121
Glycaemic index as part of the diabetes prevention strategy119
Healthy weight for the next generation's health in China117
Cardiovascular mortality trends among people with and without diabetes117
The urgent need for a diabetes data rights charter116
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing110
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply110
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history110
Correction to Lancet Diabetes Endocrinol 2025; 13: 935–48108
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials104
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study103
Diabetes and mental health103
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7101
Correction to Lancet Diabetes Endocrinol 2025; published online Nov 19. https://doi.org/10.1016/S2213-8587(25)00289-X99
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England98
Putting wellbeing at the core of diabetes care97
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin95
Are we closer to surpassing residual renal risk in type 2 diabetes?93
The role of nurses in diabetes care: challenges and opportunities93
Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement91
Bearing metabolism in mind: towards integrated care91
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial89
The promise and hope of GLP-1 receptor agonists89
Explaining the high rate of progression from prediabetes to type 2 diabetes in China89
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study88
A roadmap for integrating mental health and diabetes services85
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial85
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis85
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses84
Understanding the mechanism of prediabetes remission in young people79
CONCEPTT to care: the science of implementation in diabetes care79
Diabetes: knowing your risk matters78
Staging prediabetes and type 2 diabetes: the time to start is now77
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study76
Male hypogonadism: pathogenesis, diagnosis, and management76
Gender equality: timely and timeless75
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction74
Improving HbA1c levels with advanced hybrid closed-loop therapy72
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?70
Is it time to re-assess the development of thyroid function reference ranges?70
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–1768
2.1884920597076